非布司他怎么用？

Its main function is to lower uric acid. For patients with gout and high uric acid, it is a good choice to take febuxostat to control uric acid during the intermittent period of gout. Usually for gout patients, the best target value for lowering uric acid when taking febuxostat is below 360 μmol/L. Therefore, during the period of taking febuxostat, the uric acid value must be monitored regularly to ensure that the uric acid value reaches the target, which is also conducive to the selection of medication dosage. However, one thing to note is that for secondary hyperuricemia, such as an increase in uric acid caused by organ transplantation, or a large accumulation of urate caused by some malignant diseases, febuxostat should not be used to lower uric acid.

How to use febuxostat? What precautions should I take while taking it?

The recommended starting dose of febuxostat tablets is 40 mg. Once a day. If after 2 weeks. The blood uric acid level is still not less than 6 mg/dl (about 360 μmol/L). It is recommended that the dose be increased to 80mg. Once a day. When administering medication. There is no need to consider the effects of food and antacids. An increase in the frequency of gout attacks often occurs during the early stages of taking febuxostat. This is because blood uric acid concentration decreases, causing urate deposited in tissues to be mobilized. To prevent gout attacks during the initial stages of treatment, it is recommended to take nonsteroidal anti-inflammatory drugs or colchicine at the same time.

If gout attacks during febuxostat treatment, there is no need to discontinue febuxostat treatment. Gout should be treated accordingly according to the patient's specific situation.

Patients who report symptoms such as fatigue, loss of appetite, right upper quadrant discomfort, soy-colored urine, or jaundice that may indicate liver damage should undergo prompt liver function testing. If a patient is found to have abnormal liver function (ALT more than 3 times the upper limit of the reference range), the medication should be discontinued and investigated to determine the possible cause. Febuxostat should not be reintroduced in these patients who have abnormal liver function tests and no other reasonable explanation.

Patients should have a liver function test (serum alanine aminotransferase [ALT], aspartate transferase [AST], alkaline phosphatase, and total bilirubin) prior to first use as a baseline level.